Suppr超能文献

相似文献

1
Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men.
J Lipid Res. 2011 Mar;52(3):558-65. doi: 10.1194/jlr.M011080. Epub 2010 Dec 1.
2
High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.
Lipids. 2002 May;37(5):445-54. doi: 10.1007/s11745-002-0916-0.
3
Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2589-600. doi: 10.1161/01.atv.17.11.2589.
4
Ezetimibe increases intestinal expression of the LDL receptor gene in dyslipidaemic men with insulin resistance.
Diabetes Obes Metab. 2016 Dec;18(12):1226-1235. doi: 10.1111/dom.12749. Epub 2016 Aug 31.
6
Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells.
Clin Exp Pharmacol Physiol. 2010 Apr;37(4):471-6. doi: 10.1111/j.1440-1681.2009.05337.x. Epub 2009 Nov 23.
10
Regulation of intestinal NPC1L1 expression by dietary fish oil and docosahexaenoic acid.
J Lipid Res. 2007 Feb;48(2):395-404. doi: 10.1194/jlr.M600325-JLR200. Epub 2006 Nov 18.

引用本文的文献

1
Identification of endophenotypes supporting outcome prediction in hemodialysis patients based on mechanistic markers of statin treatment.
Heliyon. 2024 May 6;10(9):e30709. doi: 10.1016/j.heliyon.2024.e30709. eCollection 2024 May 15.
3
Adverse outcome pathway for pregnane X receptor-induced hypercholesterolemia.
Arch Toxicol. 2023 Nov;97(11):2861-2877. doi: 10.1007/s00204-023-03575-4. Epub 2023 Aug 29.
5
Nonfasting remnant cholesterol and cardiovascular disease risk prediction in Albertans: a prospective cohort study.
CMAJ Open. 2023 Jul 25;11(4):E645-E653. doi: 10.9778/cmajo.20210318. Print 2023 Jul-Aug.
6
Macrophage inhibitory cytokine-1 aggravates diet-induced gallstone formation via increased ABCG5/ABCG8 expression.
PLoS One. 2023 Jun 13;18(6):e0287146. doi: 10.1371/journal.pone.0287146. eCollection 2023.
10
Association of Kidney Function with Serum Levels of Cholesterol Absorption and Synthesis Markers: The CACHE Study CKD Analysis.
J Atheroscler Thromb. 2022 Dec 1;29(12):1835-1848. doi: 10.5551/jat.63311. Epub 2022 Mar 5.

本文引用的文献

1
Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells.
Clin Exp Pharmacol Physiol. 2010 Apr;37(4):471-6. doi: 10.1111/j.1440-1681.2009.05337.x. Epub 2009 Nov 23.
3
A new method for measurement of total plasma PCSK9: clinical applications.
J Lipid Res. 2010 Jan;51(1):140-9. doi: 10.1194/jlr.M900273-JLR200.
4
Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia.
J Lipid Res. 2009 Jul;50(7):1463-71. doi: 10.1194/jlr.P800061-JLR200. Epub 2009 Mar 22.
5
PCSK9 as a therapeutic target of dyslipidemia.
Expert Opin Ther Targets. 2009 Jan;13(1):19-28. doi: 10.1517/14728220802600715.
6
HNF4alpha is a crucial modulator of the cholesterol-dependent regulation of NPC1L1.
Pharm Res. 2008 May;25(5):1134-41. doi: 10.1007/s11095-007-9496-9. Epub 2007 Dec 14.
7
Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men.
Clin Endocrinol (Oxf). 2008 Apr;68(4):536-41. doi: 10.1111/j.1365-2265.2007.03080.x. Epub 2007 Oct 31.
8
Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism.
J Lipid Res. 2007 Aug;48(8):1746-53. doi: 10.1194/jlr.M700067-JLR200. Epub 2007 May 27.
9
The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.
Traffic. 2007 Jun;8(6):718-32. doi: 10.1111/j.1600-0854.2007.00562.x. Epub 2007 Apr 25.
10
The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin.
J Lipid Res. 2007 Mar;48(3):699-708. doi: 10.1194/jlr.M600439-JLR200. Epub 2006 Nov 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验